Abstract
Background & Aims People who inject drugs (PWID) are at high risk for acquiring and transmitting hepatitis C virus (HCV). Direct-acting antiviral (DAA) therapy leads to high cure rates. However, the lack of protective immunity after cure and high rates of reinfection in PWID necessitates access to multiple DAA treatments per PWID to reach the World Health Organization goal of HCV elimination, defined as 90% HCV incidence reduction. A major public health concern is that once the elimination goal is met, treatment of PWID will be stopped or significantly limited by a reduction in resources and complacency.
Methods We refined and extended our agent-based model to study the effects of varying levels of DAA treatment among HCV-infected PWID from Chicago, IL and the effects of stopping or reducing DAAs treatment after elimination is reached. The model uses individual temporal viral load profiles to determine transmission probabilities relative to the HCV RNA titers of receptive syringe-sharing PWID.
Results Modeling predicts that insufficient annual DAA treatment (≤2.5%, 25 per 1000 PWID) risks increasing HCV incidence. Elimination can be achieved within 10 years with annual treatment of ≥7.5%. When DAA treatment is stopped, the rate of new chronic HCV infections rapidly increases, exceeding the elimination goal within 12 months and returns to pre-elimination levels within 5 years. Annual treatment of ≥0.5% would maintain the elimination goal. This equates to identifying and treating 160 infected people in a PWID population of 32,000 each year, which would be highly resource intensive.
Conclusion The challenge to maintain the elimination goal once met, underscores the importance of augmenting DAA treatment with interventions strategies such as syringe service programs and vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health grants R01AI158666 (J.O., B.B., and H.D.) and R01AI078881 (H.D.). Intramural Food and Drug Administration funding to program Z01 BK 04010-18LHV, project 04774 (M.M.). The funders of the study had no role in study design, data analysis, interpretation of the results, or writing the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The individual data used for in host kinetics during acute infection is aggregated data. The in host viral kinetics during DAA treatment is individual-level data that had been de-identified prior to its use in this study. The synthetic population is constructed from a meta-analysis of multiple studies on PWID.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data and code used for running experiments, model fitting, and plotting are available on our GitHub repository.
